Enzalutamide: A Review in Castration-Resistant Prostate Cancer
Oral enzalutamide (Xtandi®), a second generation androgen receptor inhibitor, is indicated for the treatment of castration-resistant prostate cancer (CRPC) in numerous countries worldwide, with specific indications in this patient population varying between individual countries. Based on extensive experience in the clinical trial and/or real-world settings, oral enzalutamide 160 mg once daily is an effective and generally well tolerated treatment in a broad spectrum of patients with CRPC, including in nonmetastatic and metastatic disease and in chemotherapy-naive and -experienced metastatic CRPC. Enzalutamide is an emerging option for the treatment of men with nonmetastatic CRPC who are at high-risk for developing metastatic disease, and remains an important first-line option in chemotherapy-naive or -experienced patients with metastatic CRPC.
During the peer review process, the manufacturer of enzalutamide was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflicts of interest
Lesley Scott is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
- 2.World Cancer Research Fund International. Prostate cancer statistics. 2018. https://www.wcrf.org/. Accessed 8 Oct 2018.
- 4.NCCN. NCCN Clinical Practice Guidelines in Onoclogy: prostate cancer. 2017. https://www.nccn.org/. Accessed 17 Nov 2018.
- 11.Astellas Pharma US Inc. Xtandi® (enzalutamide) capsules, for oral use: US prescribing information. 2018. https://www.astellas.us/. Accessed 12 Nov 2018.
- 12.European Medicines Agency. Xtandi (enzalutamide): summary of product characteristics. 2018. http://www.ema.europa.eu. Accessed 12 Nov 2018.
- 15.Antonarakis ES, Lu C, Luber B, et al. Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. J Clin Oncol. 2017;35(19):2149–56.PubMedPubMedCentralGoogle Scholar
- 18.Scher HJ, Graf RP, Hulling M, et al. Use of nuclear-localized androgen receptor splice variant 7 protein in CTCs after 1st androgen receptor signaling inhibitor (ARSi) as a predictive biomarker for overall survival on a second ARSi or taxane chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) [abstract no. 836P]. Ann Oncol. 2018;29(Suppl 8):viii292.Google Scholar
- 20.Fizazi K, Hussain M, Saad F, et al. A phase III randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic (MO) castration-reistant prostate cancer (CRPC): results of PROSPER by age and region [abstract no. 805P]. Ann Oncol. 2018;29(Suppl 8):viii277.Google Scholar
- 21.Shore N, Saad F, Hussain M, et al. The PROSPER trial: chemotherapy-related endpoints in patients with nonmetastatic castration-resistant prostate cancer treated with enzalutamide [abstract no. PD10-09]. J Urol. 2018;199(4 Suppl):e231.Google Scholar
- 22.Tombal B, Hussain A, Penson D, et al. Prolonged urinary and bowel symptom control in men with nonmetastatic castration-resistant bowel cancer (nmCRPC) treated with enzaluatmide: results from the PROSPER study [abstract no. 807P]. Ann Oncol. 2018;29(Suppl 8):viii278.Google Scholar
- 23.Saad F, Penson D, Attard G, et al. Impact of enzalutamide on pain and health-related quality of life in men with non-metastatic castration-resistant prostate cancer: PROSPER study results [abstract no. MP52-19]. J Urol. 2018;199(4 Suppl):e703.Google Scholar
- 30.Alumkal JJ, Chowdhury S, Loriot Y, et al. Effect of visceral disease site on outcomes in patients with metastatic castration-resistant prostate cancer treated with enzalutamide in the PREVAIL trial. Clin Genitourin Cancer. 2017;15(5):610.e3–617.e3.Google Scholar
- 36.Skaltsa K, Ivanescu C, Naidoo S, et al. Adjusting overall survival after treatment switching: a case study in metastatic castration-resistant prostate cancer. Targ Oncol. 2017;12:111–21.Google Scholar
- 37.Bryce AH, Alumkal JJ, Armstrong A, et al. Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. Prostate Cancer Prostat Dis. 2017;20:221–7.Google Scholar
- 38.Loriot Y, Miller K, Sternberg CN, et al. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. Lancet Oncol. 2015;16(5):509–21.PubMedGoogle Scholar
- 39.Devlin N, Herdman M, Pavesi M, et al. Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial. Health Qual Life Outcomes. 2017;15(130):1–9.Google Scholar
- 41.Saad F, Ivanescu C, Phung D, et al. Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials. Prostate Cancer Prostat Dis. 2017;20:110–6.Google Scholar
- 49.Armstrong AJ, Saad F, Phung, et al. Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel. Cancer. 2017;123(12):2303–11.PubMedPubMedCentralGoogle Scholar
- 54.Penson DF, Armstrong AJ, Concepcion RS, et al. Sensitivity analyses for progression-free survival (PFS) and radiographic PFS (rPFS) from the phase II STRIVE trial comparing enzalutamide (ENZA) with bicalutamide (BIC) in men with castration-resistant prostate cancer (CRPC) [abstract no. 169]. J Clin Oncol. 2016;34(2 Suppl):e169.Google Scholar
- 55.Thiery-Vuillemin A, Hvid Poulsen M, Lagneau E, et al. Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study. ESMO Open. 2018;3(5):e000397.PubMedPubMedCentralGoogle Scholar
- 56.Miyake H, Hara T, Terakawa T, et al. Comparative assessment of clinical outcomes between abiraterone acetate and enzalutamide in patients with docetaxel-naive metastatic castration-resistant prostate cancer: experience in real-world clinical practice in Japan. Clin Genitourin Cancer. 2017;15(2):313–9.PubMedGoogle Scholar
- 60.Cheng HH, Gulati R, Azad A, et al. Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. Prostate Cancer Prostat Dis. 2015;18(2):122–7.Google Scholar
- 62.Moses KA, Penson DF, Schultz NM, et al. Real-world study of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA) or abiraterone acetate plus prednisone (AA+P): patient characteristics and treatment persistence [abstract no. e16542]. J Clin Oncol. 2017;35(15 Suppl):112.Google Scholar
- 66.Dharmani C, Bonafede M, Krivoshik A. Risk factors for and incidence of seizures in metastatic castration-resistant prostate cancer: a real-world retrospective cohort study. Clin Drug Invest. 2017;37:1183–90.Google Scholar
- 67.Azad A, Saad F, Chowdhury S, et al. Fatigue in men with metastatic castration-resistant prostate cancer treated with enzalutamide: data from randomized clinical trials [abstract no. 102]. Asia Pac J Clin Oncol. 2017;13(Suppl 1):41.Google Scholar
- 68.Quek RGW, Gilligan AM, Kent ST, et al. Hospital admissions (HA) among chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) patients newly treated with enzalutamide (ENZA) or abiraterone (ABI) [abstract no. e16524]. J Clin Oncol. 2017;35:15 Suppl.Google Scholar
- 69.Cookson MS, Roth BJ, Dahm P, et al. Castration-resistant prostate cancer: AUA guideline. 2018. https://www.auanet.org/. Accessed 15 Oct 2018.
- 70.European Medicines Agency. Meeting highlights from the Committee for Medicinal Products for Human use (CHMP) 12–15 November 2018. 2018. http://www.ema.europa.eu. Accessed 26 Nov 2018.
- 73.McCool R, Fleetwood K, Glanville J, et al. Systematic review and network meta-analysis of treatments for chemotherapy-naive patients with asymptomatic/mildly symptomatic metastatic castration-resistant prostate cancer. Value Health. 2018. https://doi.org/10.1016/j.jval.2018.03.012.PubMedGoogle Scholar
- 74.Kang M, Jeong CW, Kwak C, et al. Comparing the clinical efficacy of abiraterone acetate, enzalutamide, and orteronel in patients with metastatic castration-resistant prostate cancer by performing a network meta-analysis of eight randomized controlled trials. Oncotarget. 2017;8(35):59690–7.PubMedPubMedCentralGoogle Scholar
- 75.Rizzo S, Galvano A, Pantano F, et al. The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: an indirect comparison of randomized controlled trials. Critic Rev Oncol-Hematol. 2017;120:227–33.Google Scholar
- 79.Hornberger J, Graf RP, Hulling M, et al. Overall survival (OS) implications for patients with mCRPC through coverage and adoption of nuclear AR-V7 testing by healthcare systems [abstract no. 848P]. Ann Oncol. 2018;29(Suppl 8):viii296.Google Scholar
- 80.NICE. Enzalutamide for treating metasatic hormone-relapsed prostate cancer before chemotherapy is indicated: TA377. 2016. http://www.nice.org.uk. Accessed 12 Nov 2018.
- 81.NICE. Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen: TA316. 2014. http://www.nice.org.uk. Accessed 12 Nov 2018.
- 83.Schultz NM, Flanders SC, Wilson S, et al. Treatment duration, healthcare resource utilization, and costs among chemotherapy-naive patients with metasatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate: a retrospective claims analysis. Adv Ther. 2018. https://doi.org/10.1007/s12325-018-0774-1.PubMedPubMedCentralGoogle Scholar